Traditional Chinese Medicine shows therapeutic potential and market growth

Research published in the journal ‘Phytotherapy Research’ indicates that various Traditional Chinese Medicine (TCM) preparations can provide significant therapeutic benefits for treating rheumatoid arthritis. Specific herbal preparations, including Baikal skullcap, white peony root, and Chinese moonseed, have been shown to suppress pro-inflammatory cytokines, reduce oxidative stress, and inhibit pathological angiogenesis. Studies associated with these treatments suggest improved joint function and reduced disease activity.

Parallel to these clinical findings, the global TCM market is projected to experience substantial growth. Market analyses estimate the global TCM market will reach approximately 92.67 billion USD in 2026, potentially rising to 131.07 billion USD by 2031. This growth, representing a compound annual growth rate of 7.18%, is driven by increasing integration into mainstream medical care, expansion in e-commerce, and rising demand for chronic disease management. While the Asia-Pacific region remains the largest market, North America is expected to see the fastest growth. Key industry players include China National Pharmaceutical Group and Beijing Tong Ren Tang.